AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15114377
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 1.250 mg twice daily (500 mg Ca2+ per tablet)
Trial: 15114377
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 1.250 mg twice daily plus 400 IU vitamin D3 b.i.d.
Trial: 9421346
Drug: Psychoeducational medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychoeducational medication management training (PMT) + cognitive psychotherapy (CP) + key‐person counselling (KC)
Trial: 8318411
Drug: Continuous chemotherapy
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous chemotherapy in biochemically defined responders
Trial: 8318411
Drug: Maintenance hormones
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maintenance hormones after 6 months
Trial: 8318411
Drug: Continue chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue chemotherapy while biochemical markers kept falling or remained normal
Trial: 3011917
Drug: Intranasal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal recombinant alpha interferon (IFN‐alpha 2b) 1,500,000 IU twice daily
Trial: 3011917
Drug: Intranasal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal recombinant alpha interferon (IFN‐alpha 2b)
Trial: 3011917
Drug: Intranasal recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal recombinant alpha interferon (IFN‐alpha 2b) or placebo once daily
Trial: 30776365
Drug: Antibiotic management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic management based on rapid diagnostic testing (RDT)
Trial: 30776365
Drug: Antibiotic management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic management based on RDT
Trial: 26715485
Drug: 40 IU
RxNorm normalized name: Oxytocin 40 IU/1 ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of intranasal OXT
Trial: 17884346
Drug: Botanical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botanical formulation (rose hips, blueberry and blackberry mixture, grapevine extract)
Trial: 17884346
Drug: Botanical formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botanical formulation
Trial: 12126522
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1.0 g/d (body weight < 50 kg) or 1.5 g/d (body weight > 50 kg), reduced to 0.75-1.0 g/d after 6 months, maintaining dosage of 0.5-0.75 g/d after 12 months, total treatment duration at least 12 months.
Trial: 12126522
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received prednisone orally at 0.8 mg/kg/d.
Trial: 10530284
Drug: Active vertical
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active vertical corrector (AVC) treatment followed by fixed 022 orthodontic appliances
Trial: 7548920
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g lactulose
Trial: 7548920
Drug: 5 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 g inulin
Trial: 7548920
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g inulin
Trial: 7548920
Drug: resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: resistant starch (6.1 g)
Trial: 6783524
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition regimen consisting of 0.6 g amino acid and 4.0 g carbohydrate/kg BW/day
Trial: 6783524
Drug: Isocaloric amounts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isocaloric amounts of carbohydrate (5.0 g/kg BW/day) alone
Trial: 31161236
Drug: 14 baths
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 baths in thermal water for a month plus standard pharmacological treatment (Group A Phase 1)
Trial: 31161236
Drug: Standard pharmacological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pharmacological treatment (Group B Phase 1)
Trial: 31161236
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (Group A Phase 2)
Trial: 31161236
Drug: 14 baths
RxNorm normalized name: colloidal oatmeal
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14 baths in thermal water for a month plus standard treatment (Group B Phase 2)
Trial: 26336909
Drug: 6-week intranasal
RxNorm normalized name: perampanel
DrugBank: Perampanel (DB08883)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6-week intranasal administration of oxytocin
Trial: 21876564
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg A3309
Trial: 17723083
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with amiodarone and sotalol
Trial: 17723083
Drug: Sotalol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol monotherapy
Trial: 17723083
Drug: Amiodarone monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone monotherapy
Trial: 8833170
Drug: Injective immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injective immunotherapy (SIT)
Trial: 3830240
Drug: FCE20700 (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE20700 (1 mg, 2 mg)
Trial: 3830240
Drug: FCE20700 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FCE20700 (2 mg)
Trial: 29722834
Drug: Caloric sweeteners
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caloric sweeteners (50 g glucose and 25 g fructose)
Trial: 29722834
Drug: Noncaloric sweetener
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncaloric sweetener (220 mg acesulfame-K)
Trial: 26494130
Drug: Panobinostat single-agent
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Panobinostat single-agent trials
Trial: 16895639
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive (OC) pretreatment with recombinant human FSH (r-hFSH) starting on day 2 or 3 after OC withdrawal.
Trial: 1373779
Drug: Finasteride (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (5 to 80 mg per day) for 12 weeks
Trial: 1373779
Drug: Finasteride (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (0.2 to 40 mg per day) for 24 weeks
Trial: 1373779
Drug: Finasteride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (1 and 5 mg groups combined)
Trial: 1373779
Drug: Finasteride (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finasteride (1 and 5 mg groups)
Trial: 4040050
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Reglan and Solu‐medrol
Trial: 25317619
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate solution (3 ml/kg of sodium bicarbonate solution (150 mEq/L) one hour prior to procedure and then drip rate decreased to 1 ml/kg/hour until 6 hours post procedure)
Trial: 25317619
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride solution (1 ml/kg/hour of normal saline solution, starting 12 hours before and continuing 12 hours after iohexol contrast)
Trial: 19602993
Drug: Light protected
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light protected parenteral nutrition
Trial: 19602993
Drug: Light exposed
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light exposed parenteral nutrition
Trial: 19083385
Drug: Beta-alanine supplementation
RxNorm normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-alanine supplementation (4.5 g x d(‐1))
Trial: 19083385
Drug: Placebo (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (4.5 g x d(‐1) of maltodextrin)
Trial: 8720611
Drug: Anthropometric characteristics,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthropometric characteristics, 2-h post-load specific insulin levels, fasting proinsulin/fasting insulin ratio
Trial: 1359258
Drug: Enalapril (2.5‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (2.5‐20 mg per day)
Trial: 3994881
Drug: Lower concentrations
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower concentrations of volatile agents
Trial: 25122121
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg tribendimidine
Trial: 25122121
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg tribendimidine twice daily
Trial: 25122121
Drug: 75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg/kg praziquantel divided in four doses within 2 days
Trial: 25122121
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg mebendazole
Trial: 16438370
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Vaxigrip and Arbidol
Trial: 25947165
Drug: Rabies vaccine
RxNorm normalized name: RABIES VACCINE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabies vaccine (control).
Trial: 24078508
Drug: Doxazosin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (2 mg at night for two weeks, increasing to 4 mg for a further two weeks)
Trial: 24078508
Drug: Intranasal desmopressin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal desmopressin (20 μg at night)
Trial: 21491106
Drug: Oral Phe
RxNorm normalized name: Phe
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Phe load (100 mg/kg body weight) administered to PKU patients prior to one fMRI session (placebo-controlled)
Trial: 21491106
Drug: Oral Phe
RxNorm normalized name: Phe
DrugBank: Phenylalanine (DB00120)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Phe load (100 mg/kg body weight)
Trial: 2655681
Drug: Frusemide 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Frusemide 100 mg
Trial: 2655681
Drug: Bumetanide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bumetanide 2.5 mg
Trial: 319892
Drug: Primary additive
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary additive hormone therapy followed by adrenalectomy
Trial: 319892
Drug: Primary adrenalectomy
RxNorm normalized name: Sodium primary phosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary adrenalectomy followed by chemotherapy and/or additive hormone therapy
Trial: 319892
Drug: Adrenalectomy-oophorectomy as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenalectomy-oophorectomy as primary mode of therapy
Trial: 319892
Drug: Sequential hormonal
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential hormonal manipulation
Trial: 28575496
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (r‐ESWT)
Trial: 19618229
Drug: Functional dysphagia
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional dysphagia therapy with PEG feeding (group 1, n=59)
Trial: 19618229
Drug: Functional dysphagia
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional dysphagia therapy without PEG feeding (group 2, n=105)
Trial: 15219637
Drug: G331A polymorphism
RxNorm normalized name: ANGELICA POLYMORPHA ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G331A polymorphism in the progesterone receptor gene
Trial: 15219637
Drug: PROGINS polymorphism
RxNorm normalized name: Angelica polymorpha root extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PROGINS polymorphism in the progesterone receptor gene
Trial: 11588508
Drug: Didanosine enteric-coated
RxNorm normalized name: didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine enteric-coated capsules (Videx EC)
Trial: 11588508
Drug: Didanosine tablets
RxNorm normalized name: didanosine Chewable Tablet
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Didanosine tablets
Trial: 9332685
Drug: Alternating chemoradiotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemoradiotherapy with cisplatin (20 mg/m2/day) and fluorouracil (200 mg/m2/day) for five consecutive days (CF)
Trial: 9332685
Drug: Alternating chemotherapy
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating chemotherapy with vinblastine and bleomycin followed by standard radiotherapy (VBM)
Trial: 9332685
Drug: Sequential VBM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential VBM and radiation
Trial: 3465787
Drug: Acetaminophen 1,000
RxNorm normalized name: Acetaminophen 1,000mg/30mL Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1,000 mg before surgery
Trial: 3465787
Drug: Acetaminophen 650
RxNorm normalized name: acetaminophen 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 650 mg administered at fixed intervals after surgery
Trial: 3465787
Drug: Acetaminophen 1,000
RxNorm normalized name: Acetaminophen 1,000mg/30mL Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1,000 mg before surgery with acetaminophen as needed after surgery
Trial: 30868491
Drug: Unchanged pharmacological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unchanged pharmacological anti-arrhythmia therapy
Trial: 26873501
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (LLLT) - 2 sessions weekly for 5 weeks, using a 980-nm AlGaAs diode laser at 300 mW, delivering a Fluence of 10 J/cm²
Trial: 26873501
Drug: Clonazepam -
RxNorm normalized name: Clonazepam
DrugBank: Clonazepam (DB01068)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clonazepam - half a tablet (2 mg) in the mouth for 3 min, three times a day for 21 days
Trial: 17620074
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with 200,000 SQ-U
Trial: 17620074
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy (SLIT) with 24,000 SQ-U
Trial: 16238883
Drug: Cognitive-behavioural anger
RxNorm normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cognitive-behavioural anger treatment (AT group)
Trial: 7605855
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg) without gastritis
Trial: 7605855
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg) with normal gastric emptying
Trial: 7324888
Drug: Paraffin‐based neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paraffin‐based neutral eye ointment Ph. Nord. 63
Trial: 21835452
Drug: GnRH (0.004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GnRH (0.004 mg buserelin)
Trial: 19421185
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) once weekly for 3 weeks
Trial: 19421185
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) once daily for 21 days
Trial: 19421185
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) at weekly doses > or = 25 mg
Trial: 19421185
Drug: Odanacatib (ODN)
RxNorm normalized name: Odanacatib
DrugBank: Odanacatib (DB06670)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Odanacatib (ODN) at daily doses > or = 2.5 mg
Trial: 15145970
Drug: M100240 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M100240 50 mg once daily
Trial: 15145970
Drug: M100240 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M100240 25 mg three times daily or 50 mg twice daily
Trial: 15145970
Drug: M100240 up
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M100240 up to 50 mg once daily
Trial: 11586054
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg trazodone
Trial: 7758394
Drug: Arbekacin (ABK)
RxNorm normalized name: arbekacin
DrugBank: Arbekacin (DB06696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbekacin (ABK) in combination with other compounds
Trial: 7758394
Drug: Arbekacin (ABK)
RxNorm normalized name: arbekacin
DrugBank: Arbekacin (DB06696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbekacin (ABK) in patients pretreated with other drugs
Trial: 28914446
Drug: Concomitant use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant use of biologic drugs
Trial: 25943574
Drug: Doublet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab
Trial: 25943574
Drug: Doublet chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doublet chemotherapy (FOLFOX or FOLFIRI) plus panitumumab
Trial: 25943574
Drug: Triple chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple chemotherapy (FOLFOXIRI) plus bevacizumab
Trial: 18261575
Drug: Alendronate +
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate + Alfacalcidol (10 mg/d + 0.5 microg/d)
Trial: 6091392
Drug: Misonidazole (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Misonidazole (11 g/m2 over four weeks)
Trial: 26081039
Drug: Rinsing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinsing with 15 ml of water for 30 seconds
Trial: 26081039
Drug: Drinking 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drinking 200 ml of water within 30 seconds
Trial: 24801218
Drug: PF‐04447943 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF‐04447943 25 mg q12h
Trial: 16209244
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (15 min duration)
Trial: 16209244
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (without music therapy)
Trial: 10336918
Drug: Sublingual glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual glyceryl trinitrate
Trial: 10336918
Drug: Sequential use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential use of tests
Trial: 2149280
Drug: Toremifene 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 200 mg/day
Trial: 2149280
Drug: Toremifene 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene 400 mg/day
Trial: 2149280
Drug: Toremifene (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (various doses)
Trial: 2149280
Drug: Toremifene (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (doses >= 40 mg/day)
Trial: 2149280
Drug: Toremifene (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (all doses tested)
Trial: 2149280
Drug: Toremifene (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene (doses >= 60 mg/day)
Trial: 7307428
Drug: Methadone (7.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone (7.5, 15, or 30 mg/70 kg)
Trial: 24880619
Drug: Intraorbital injections
RxNorm normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraorbital injections of rituximab (RTX)
Trial: 24880619
Drug: Intravenous glucocorticoids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous glucocorticoids (GCs)
Trial: 22737998
Drug: Intravitreal ranibizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal ranibizumab injection (0.05 mL)
Trial: 19836952
Drug: Aromatase inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitors (specific dosage and duration not mentioned)
Trial: 12926979
Drug: Topical agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical agents (aluminum chloride) and iontophoresis